Logo image of VX1.DE

VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis

Europe - FRA:VX1 - US92532F1003 - Common Stock

353.775 EUR
+0.92 (+0.26%)
Last: 10/15/2025, 5:05:17 PM
Fundamental Rating

6

VX1 gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 79 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making VX1 a very profitable company, without any liquidiy or solvency issues. VX1 is growing strongly while it is still valued neutral. This is a good combination! With these ratings, VX1 could be worth investigating further for growth and quality investing!.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

VX1 had positive earnings in the past year.
VX1 had a positive operating cash flow in the past year.
Of the past 5 years VX1 4 years were profitable.
Of the past 5 years VX1 4 years had a positive operating cash flow.
VX1.DE Yearly Net Income VS EBIT VS OCF VS FCFVX1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

Looking at the Return On Assets, with a value of 15.13%, VX1 belongs to the top of the industry, outperforming 86.08% of the companies in the same industry.
VX1 has a better Return On Equity (21.18%) than 88.61% of its industry peers.
VX1 has a better Return On Invested Capital (15.66%) than 89.87% of its industry peers.
VX1 had an Average Return On Invested Capital over the past 3 years of 17.53%. This is above the industry average of 15.27%.
Industry RankSector Rank
ROA 15.13%
ROE 21.18%
ROIC 15.66%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
VX1.DE Yearly ROA, ROE, ROICVX1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

1.3 Margins

With an excellent Profit Margin value of 31.86%, VX1 belongs to the best of the industry, outperforming 87.34% of the companies in the same industry.
Looking at the Operating Margin, with a value of 38.77%, VX1 belongs to the top of the industry, outperforming 92.41% of the companies in the same industry.
VX1's Operating Margin has improved in the last couple of years.
The Gross Margin of VX1 (86.11%) is better than 77.22% of its industry peers.
VX1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 38.77%
PM (TTM) 31.86%
GM 86.11%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
VX1.DE Yearly Profit, Operating, Gross MarginsVX1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), VX1 is creating value.
Compared to 1 year ago, VX1 has less shares outstanding
Compared to 5 years ago, VX1 has less shares outstanding
Compared to 1 year ago, VX1 has an improved debt to assets ratio.
VX1.DE Yearly Shares OutstandingVX1.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
VX1.DE Yearly Total Debt VS Total AssetsVX1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

There is no outstanding debt for VX1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.67
WACC9.39%
VX1.DE Yearly LT Debt VS Equity VS FCFVX1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

A Current Ratio of 2.52 indicates that VX1 has no problem at all paying its short term obligations.
VX1 has a Current ratio of 2.52. This is comparable to the rest of the industry: VX1 outperforms 55.70% of its industry peers.
A Quick Ratio of 2.16 indicates that VX1 has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.16, VX1 is in line with its industry, outperforming 53.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.52
Quick Ratio 2.16
VX1.DE Yearly Current Assets VS Current LiabilitesVX1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B

7

3. Growth

3.1 Past

VX1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 7966.67%, which is quite impressive.
Measured over the past years, VX1 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -44.14% on average per year.
Looking at the last year, VX1 shows a quite strong growth in Revenue. The Revenue has grown by 10.46% in the last year.
Measured over the past years, VX1 shows a very strong growth in Revenue. The Revenue has been growing by 21.50% on average per year.
EPS 1Y (TTM)7966.67%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%135.23%
Revenue 1Y (TTM)10.46%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%12.06%

3.2 Future

Based on estimates for the next years, VX1 will show a very strong growth in Earnings Per Share. The EPS will grow by 150.50% on average per year.
The Revenue is expected to grow by 9.58% on average over the next years. This is quite good.
EPS Next Y6246.89%
EPS Next 2Y746.68%
EPS Next 3Y328.73%
EPS Next 5Y150.5%
Revenue Next Year10.06%
Revenue Next 2Y9.8%
Revenue Next 3Y9.54%
Revenue Next 5Y9.58%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
VX1.DE Yearly Revenue VS EstimatesVX1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B 15B 20B
VX1.DE Yearly EPS VS EstimatesVX1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20 30

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 24.13 indicates a rather expensive valuation of VX1.
Based on the Price/Earnings ratio, VX1 is valued a bit cheaper than 79.75% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.49, VX1 is valued at the same level.
The Price/Forward Earnings ratio is 19.66, which indicates a rather expensive current valuation of VX1.
Based on the Price/Forward Earnings ratio, VX1 is valued cheaper than 84.81% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.99, VX1 is valued at the same level.
Industry RankSector Rank
PE 24.13
Fwd PE 19.66
VX1.DE Price Earnings VS Forward Price EarningsVX1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

VX1's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. VX1 is cheaper than 75.95% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of VX1 indicates a rather cheap valuation: VX1 is cheaper than 81.01% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 29.94
EV/EBITDA 21.21
VX1.DE Per share dataVX1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
VX1 has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as VX1's earnings are expected to grow with 328.73% in the coming years.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y746.68%
EPS Next 3Y328.73%

0

5. Dividend

5.1 Amount

No dividends for VX1!.
Industry RankSector Rank
Dividend Yield N/A

VERTEX PHARMACEUTICALS INC

FRA:VX1 (10/15/2025, 5:05:17 PM)

353.775

+0.92 (+0.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04 2025-08-04/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners98.11%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap90.70B
Analysts76.41
Price Target418.38 (18.26%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.87%
Min EPS beat(2)-7.2%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.78%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.69%
EPS beat(8)5
Avg EPS beat(8)-64.35%
EPS beat(12)7
Avg EPS beat(12)-42%
EPS beat(16)10
Avg EPS beat(16)-30.64%
Revenue beat(2)1
Avg Revenue beat(2)-2.37%
Min Revenue beat(2)-4.8%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.57%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.87%
Revenue beat(12)5
Avg Revenue beat(12)-0.45%
Revenue beat(16)8
Avg Revenue beat(16)0.05%
PT rev (1m)-1.56%
PT rev (3m)-6.41%
EPS NQ rev (1m)-0.4%
EPS NQ rev (3m)-0.39%
EPS NY rev (1m)-0.15%
EPS NY rev (3m)0.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.39%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)0.45%
Valuation
Industry RankSector Rank
PE 24.13
Fwd PE 19.66
P/S 9.18
P/FCF 29.94
P/OCF 27.24
P/B 6.1
P/tB 6.7
EV/EBITDA 21.21
EPS(TTM)14.66
EY4.14%
EPS(NY)17.99
Fwd EY5.09%
FCF(TTM)11.82
FCFY3.34%
OCF(TTM)12.99
OCFY3.67%
SpS38.55
BVpS57.98
TBVpS52.84
PEG (NY)0
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 15.13%
ROE 21.18%
ROCE 22.25%
ROIC 15.66%
ROICexc 23.06%
ROICexgc 25.99%
OM 38.77%
PM (TTM) 31.86%
GM 86.11%
FCFM 30.65%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.53%
ROIC(5y)18.06%
ROICexc(3y)43.35%
ROICexc(5y)48.92%
ROICexgc(3y)62.02%
ROICexgc(5y)75.97%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexcg growth 3Y-29.98%
ROICexcg growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score6
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 173.52%
Cap/Sales 3.04%
Interest Coverage 260.41
Cash Conversion 83.13%
Profit Quality 96.21%
Current Ratio 2.52
Quick Ratio 2.16
Altman-Z N/A
F-Score6
WACC9.39%
ROIC/WACC1.67
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7966.67%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%135.23%
EPS Next Y6246.89%
EPS Next 2Y746.68%
EPS Next 3Y328.73%
EPS Next 5Y150.5%
Revenue 1Y (TTM)10.46%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%12.06%
Revenue Next Year10.06%
Revenue Next 2Y9.8%
Revenue Next 3Y9.54%
Revenue Next 5Y9.58%
EBIT growth 1Y4.24%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year820.09%
EBIT Next 3Y129.43%
EBIT Next 5Y68.38%
FCF growth 1Y-9.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.45%
OCF growth 3YN/A
OCF growth 5YN/A